SEARCH

SEARCH BY CITATION

References

  • 1
    Gane E, Portmann B, Naoumov N, Smith H, Underhill J, Donaldson P, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334:821827.
  • 2
    Feray C, Caccamo L, Alexander G, Ducot B, Gugenheim J, Casanovas T, et al. HCV and liver transplantation: Preliminary results of a European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. Gastroenterology 1999; 117:619625.
  • 3
    Forman L, Lewis J, Berlin J, Feldman H, Lucey M. Association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122:889896.
  • 4
    Sanchez-Fueyo A, Restrepo J, Qunito L, Bruguera M, Grande L, Sanchez-Tapias J, et al. Impact of recurrence of HCV infection after liver transplantation on the long-term viability of the graft. Transplantation 2002; 73:5663.
  • 5
    Berengeur M, Prieto M, Rayon J, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32:852858.
  • 6
    Pruthi J, Medkiff KA, Esrason K, Donovan JA, Yoshida EM, Erb SR, et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl 2001; 7:811815.
  • 7
    Roayaie S, Schiano T, Kim-Shugler L, Emre S, Fishbein T, Miller C, Schwartz M. Results of retransplantation for recurrent HCV [abstract]. Am J Transplant 2002; 2:106A.
  • 8
    Chazouilleres O, Kim M, Coombs C, Ferrell L, Bacchetti P, Roberts J, et al. Quantitation of HCV RNA in liver transplant recipients. Gastroenterology 1994; 106:994999.
  • 9
    Gane E, Naoumov N, Qian K, Mondelli M, Maertens G, Portmann B, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110:167177.
  • 10
    Everhart J, Wei Y, Eng H, Charlton M, Persing D, Wiesner R, et al. Recurrent and new HCV infection after liver transplantation. Hepatology 1999; 29:12201226.
  • 11
    Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, et al. Hepatitis C virus kinetics during and after liver transplantation. Hepatology 2002; 35:680687.
  • 12
    Wright HGJ, Van Thiel D. Preliminary experience with alpha 2-b interferon therapy of viral hepatitis in liver allograft recipients. Transplantation 1992; 53:121124.
  • 13
    Wright T, Combs C, Kim M, Ferrell L, Bacchetti P, Ascher N, et al. Interferon-α therapy for hepatitis C virus infection after liver transplantation. Hepatology 1994; 20:773779.
  • 14
    Feray C, Samuel D, Gigou M, Paradis V, Reynes M, Bismuth H. An open trial of interferon-α recombinant for hepatitis C after liver transplantation. Hepatology 1995; 22:10841089.
  • 15
    Gane E, Lo SK, Portmann BC, Riordan SM, Lau JYN, Naoumov NV, Williams R. A randomised study comparing ribavirin and interferon-alpha monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998; 27:14031407.
  • 16
    Cotler S, Ganger D, Kaur S, Rosenblate H, Jakate S, Sullivan D, et al. Daily interferon for HCV infection in liver transplant recipients. Transplantation 2001; 71:261266.
  • 17
    Sidwell R, Hoffman J, Karp L. Broad spectrum activity of virazole 1-b-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 1972; 117:705706.
  • 18
    Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, et al. Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study. J Hepatol 1996; 25:591598.
  • 19
    Bodenheimer HC, Lindsay KKL, Davis GL, Lewis JH, Thung SN, Mahaney K, Seef L. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicentre trial. Hepatology 1997; 26:473477.
  • 20
    Di Bisceglie AM, Conjeevaram HA, Fried MW, Sallie R, Park Y, Yurdaydin C, et al. Ribavirin as therapy for chronic hepatitis C. Ann Intern Med 1995; 123:897903.
  • 21
    Quadri R, Giostra E, Roskams T, Pawlotsky J, Mentha G, Rubbia-Brandt L, et al. Immunological and virological effects of ribavirin in hepatitis C after liver transplantation. Transplantation 2002; 73:373378.
  • 22
    Gane E, Tibbs C, Ramage J, Portmann B, Williams R. Ribavirin therapy for hepatitis C infection following liver transplantation. Transpl Int 1995; 8:6164.
  • 23
    Cattral MS, Krajden M, Wanless IR, Rezig M, Cameron R, Greig PD, et al. A pilot study of ribavirin therapy for recurrent hepatitis C virus infection after liver transplantation. Transplantation 1996; 61:14831488.
  • 24
    Ilyin G, Langouet S, Rissel M, Delcros J, Guillouzo A, Guguen-Guillouzo C. Ribavirin inhibits protein synthesis and cell proliferation induced by mitogenic factors in primary human and rate hepatocytes. Hepatology 1998; 27:16871694.
  • 25
    Ning Q, Brown D, Parado J, Cattral M, Gorczynski R, Cole E, et al. Ribavirin inhibits viral-induced macrophage production of TNF-α, IL-1, fg12 prothrombinase and preserves TH1 cytokine production but inhibits a TH2 cytokine response. J Immunol 1998; 160:34873493.
  • 26
    Hultgren C, Milich D, Weiland O, Sallberg M. The antiviral compound ribavirin modulates the T helper (Th)1/Th2 subset balance in hepatitis band C virus-specific immune responses. J Gen Virol 1998; 79:23812391.
  • 27
    Fang SH, Hwang LH, Chen DS, Chiang BL. Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level. J Hepatol 2000; 33:791798.
  • 28
    Tam R, Pai B, Bard J, Lim J Averett D, Phan U, Milovanivic T. Ribavirin polarises human T-cell responses. J Hepatol 1999; 30:376382.
  • 29
    Cramp M, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov N. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000; 118:346355.
  • 30
    McHutchinson J, Gordon S, Schiff E, Schiffman M, Lee W, Rustgi V, et al. Interferon 2b alone or in combination with ribavirin as initial treatment of chronic hepatitis C. N Engl J Med 1998; 339:14851492.
  • 31
    Bizollon T, Palazzo U, Ducerf C, Chevallier M, Elliot M, Pouyet M, Trepo C. Pilot study of combination of interferon alpha and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997; 26:500504.
  • 32
    Zamboni F, Franchello A, Lavezzo B, Strignano P, Schellino M, Rizzetto M, Salizzoni M. Treatment of recurrent hepatitis C after liver transplantation with interferon alfa 2b and ribavirin [abstract]. J Hepatol 2000; 32(suppl 1):265.
  • 33
    Bellati G, Alberti A, Belli L, Vai C, Airoldi A, Rondinara G, et al. Therapy of chronic hepatitis C after liver transplantation: Multicentre Italian experience [abstract]. J Hepatol 1999; 30(suppl 1):51.
  • 34
    Ahmad J, Dodson S, Demetris A, Fung J, Shakil A. Recurrent hepatitis C after liver transplantation: A nonrandomised trial of interferon alfa alone versus interferon alfa plus ribavirin. Liver Transpl 2001; 7:863869.
  • 35
    Gopal D, Rabkin J, Berk B, Corless C, Chou S, Olyaei A. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin. Liver Transpl 2001; 7:181190.
  • 36
    Alberti A, Belli L, Airoldi A, de Carlis L, Rondinara G, Minola E, et al. Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: A pragmatic study. Liver Transpl 2001; 7:870876.
  • 37
    De Vera M, Smallwood G, Rosado K, Davis L, Martinez E, Sharma S, et al. Interferon and ribavirin for treatment of recurrent hepatitis C after liver transplantation. Transplantation 2001; 71:678686.
  • 38
    Menon K, Poterucha J, El-Amin O, Burgart L, Kremers W, Rosen C, et al. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: Lessons in tolerability and efficacy. Liver Transpl 2002; 8:623629.
  • 39
    Samuel D, Bizillon T, Feray C, Ahmed S, Cohard M, Bismuth H, Trepo C. Combination interferon-alpha and ribavirin for recurrent HCV infection after liver transplantation: A randomised controlled study [abstract]. Hepatology 2000; 32:542A.
  • 40
    Zeuzem S, Feinman SW, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon α-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343:16661672.
  • 41
    Ferenci P, Peck-Radosavljevic M, Vogel W, Graziadei I, Riely C, Voigt MD, et al. 40kDA Peginterferon alfa-2a (Pegasys) in post-liver transplant recipients with established recurrent hepatitis C: Preliminary results of a randomized multicenter trial [abstract]. Hepatology 2001; 34:406A.
  • 42
    Hadziyannis S, Cheinquer H, Morgan T, Diago M, Jensen D, Sette H, et al. Peginterferon alfa-2a in combination with ribavirin [abstract]. J Hepatol 2002; 36(suppl 1):3.
  • 43
    Manns M, McHutchinson J, Gordon S, Rustgi V, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C. Lancet 2001; 358:958965.
  • 44
    Hassanein T, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai M-Y, et al. Treatment with 40kDA peginterferon alpha 2a in combination with ribavirin significantly enhances quality of life compared with interferon alpha 2b plus ribavirin [abstract]. Hepatology 2001; 34:243A.
  • 45
    Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM. Hepatitis C, interferon alfa and depression. Hepatology 2000; 31:12071211.
  • 46
    Singh N, Gayowski T, Wagener M, Marino I. Quality of life, functional status, and depression in male liver transplant recipients with recurrent viral hepatitis C. Transplantation 1999; 67:6972.
  • 47
    De Bona M, Ponton P, Ermani M, Iemmolo R, Feltrin A, Boccagni P, et al. The impact of liver disease and medical complications on quality of life and psychological distress before and after liver transplantation. J Hepatol 2000; 33:609615.
  • 48
    Forton D, Allsop J, Main J, Foster G, Thomas H, Taylor-Robinson S. Evidence for a cerebral effect of HCV. Lancet 2001; 358:3839.
  • 49
    Musselman D, Lawson D, Gumnick J, Manatunga A, Oenna S, Goodkin R, et al. Paroxetine for the prevention of depression induced by high-dose interferon. N Engl J Med 2001; 34:961966.
  • 50
    Slater A, Klein J, Sonnerfield G, Ogden L, Gray L. The effects of interferon in a model of rat heart transplantation. J Heart Lung Transpl 1992; 11:975978.
  • 51
    Rostaing L, Modesto A, Baron E, Cisterne JM, Chabannier MH, Durand D. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996; 74:512516.
  • 52
    Kramer P, ten Kate FW, Bijnen AB, Jeekel J, Weimar W. Recombinant leucocyte interferon induces steroid-resistant acute vascular rejection episodes in renal transplant recipients. Lancet 1984; 1:989990.
  • 53
    Magnone M, Holley J, Shapiro R, Scantlebury V, McCauley J, Jordan M, et al. Interferon-alpha-induced acute renal allograft rejection. Transplantation 1995; 59:10681070.
  • 54
    Jain A, Demetris A, Manez R, Tsamamadas A, van Thiel D, Rakela J, et al. Incidence and severity of acute allograft rejection in liver transplant recipients treated with alfa interferon. Liver Transpl Surg 1998; 4:197203.
  • 55
    Singh N, Gayowski T, Wannstedt C, Shakil O, Wagener M, Fung J, Marino I. Interferon-α for prophylaxis of recurrent HCV in liver transplant recipients. Transplantation 1998; 65:8286.
  • 56
    De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, et al. Haemolytic anaemia induced by ribavirin therapy in patients with chronic HCV infection: Role of membrane oxidative damage. Hepatology 2000; 31:9971004.
  • 57
    Reddy R, Fried M, Dickson R, Martin P, Schiff E, Torres M, et al. Interferon alfa-2b and ribavirin vs placebo as early treatment in patients transplanted for hepatitis C end-stage liver disease: Results of multicenter, randomized trial [abstract]. Gastroenterology 2002; 122:199A.
  • 58
    Garnier JL, Chevallier P, Dubernard JM, Trepo C, Touraine JL, Chossegros P. Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients. Transplant Proc 1997; 29:783.
  • 59
    Daoud S, Garnier JL, Chossegros P, Chevallier P, Dubernard JM, Touraine JL. Hepatitis C virus infection in renal transplantation. Transplant Proc 1995; 27:1735.
  • 60
    Mazzaferro V, Coppa J, Schiavo M, Regalia E, Pulvrenti A, Ribero M, et al. Prevention of recurrent HCV after liver transplantation with early interferon-α 2b and ribavirin. Transplant Proc 2001; 33:13551357.
  • 61
    Talal AH, Weisz K, Hau T, Kreiswirth S, Dieterich DT. A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-alpha. Am J Gastroenterol 2001; 96:28022804.
  • 62
    Gergely A, Lafarge P, Fouchard-Hubert I, Fabiani F. Treatment of interferon/ribavirin induced anaemia with erythropoietin. Hepatology 2002; 35:12811282.
  • 63
    Pelletier S, Raymond D, Crabtree T, Berg C, Iezonni J, Hahn Y, et al. Hepatitis C-induced hepatic allograft injury is associated with a pretransplantation elevated viral replication rate. Hepatology 2000; 32:418426.
  • 64
    Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28:823830.
  • 65
    Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles K, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348:12121215.
  • 66
    Markowitz J, Martin P, Conrad A, Markmann J, Seu P, Yersiz H, et al. Prophylaxis against HBV recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28:585589.
  • 67
    Lock G, Reng C, Graeb C, Anthuber M, Wiedmann K. Interferon-induced hepatic failure in a patient with hepatitis C. Am J Gastroenterol 1999; 94:25702571.
    Direct Link:
  • 68
    Crippin J, McCashand T, Terrault N, Sheiner P, Charlton M. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C-infected patients awaiting liver transplantation. Liver Transpl 2002; 4:350355.
  • 69
    Everson G, Trouillot T, Trotter J, Halprin A, McKinley C, Fey B, Epp J. Treatment of decompensated cirrhotics with a low dose regimen of interferon plus ribavirin [abstract]. Hepatology 2000; 32:308A.
  • 70
    Halprin A, Trotter J, Everson G, Wachs M, Bak T, Kugelmas M, Kam I. Posttransplant eradication by pretransplant treatment in living donor liver transplant recipients [abstract]. Hepatology 2001; 34:244A.
  • 71
    Jaekel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al. Treatment of acute hepatitis C with interferon-alpha 2b. N Engl J Med 2001; 345:14521457.
  • 72
    Moribe T, Hayashi N, Kanazawa Y, Mita E, Fusamoto H, Negi M, et al. Hepatitis C viral complexity detected by single strand conformation polymorphism and response to interferon therapy. Gastroenterology 1995; 108:789795.
  • 73
    Forns X, Garcia M, Feliu A, Moitinho E, Costa J, Navasa M, Rodes J. HCV kinetics and quasispecies evolution during and immediately after liver transplantation [abstract]. Hepatology 2001; 34:362A.
  • 74
    Ballardini G, de Raffele E, Groff P, Bioulac-Sage P, Grassi A, Ghetti S, et al. Timing of reinfection and mechanisms of hepatocellular damage in transplanted HCV-infected liver. Liver Transpl 2002; 8:1020.
  • 75
    Sheiner P, Boros P, Klion F, Thung S, Schugler L, Lau J, et al. The efficacy of prophylactic interferon-α in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998; 28:831838.
  • 76
    Martin P, Mitra S, Martin N. Pegylated (40KDA) interferon alpha-2A (Pegasys™) is unaffected by renal impairment [abstract]. Hepatology 2000; 32:370A.
  • 77
    Manzarbeitia C, Tepermann L, Chalasani N, Sheiner P, Wiesner R, Marks I, et al. 40kDA peginterferon as prophylaxis against HCV recurrence after liver transplantation: Preliminary results of a randomised, multicentre trial [abstract]. Hepatology 2001; 34:406A.
  • 78
    Feray C, Gigou M, Samuel D, Ducot B, Maisonneuve P, Reynes M, et al. Incidence of hepatitis C in patients receiving immunoglobulins after liver transplantation. Ann Intern Med 1998; 128:810816.
  • 79
    Krawczynski K, Alter M, Tankersley D, Beach M, Robertson B, Lambert S, et al. Effect of immune globulin on prevention of experimental HCV infection. J Infect Dis 1996; 173:822828.
  • 80
    Willems B, Ede M, Marotta P, Greig P, Lilly L, Kneteman N, et al. Anti-HCV immunoglobulins for the prevention of graft infection in HCV-related liver transplantation [abstract]. J Hepatol 2002; 36(suppl 1):S96A.
  • 81
    Tam R, Ramasamy K, Bard J, Pai B, Lim C, Averett D. Ribavirin analogue ICN 17261 demonstrates reduced toxicity with retention of both immunomodulatory activity and reduction of ALT levels. Antimicrob Agents Chemother 2000; 44:12761283.
  • 82
    Haig P, Mullerova I, Tang K, Proto S, Chokshi S, Williams R, et al. Analysis of the immunomodulatory activity of levovirin, a second generation ribavirin analogue, on T-cell responses [abstract]. J Hepatol 2002; 36(suppl 1):24.
  • 83
    Rossi S, Wright T, Lin C, Lau J, Edalatpour N, Fang J. Phase 1 clinical studies of levovirin—A second generation ribavirin candidate [abstract]. Hepatology 2001; 34:327A.
  • 84
    Neyts J, De Clercq E. Mycophenylate mofetil strongly potentiates the antiherpesvirus activity of acyclovir. Antivir Res 1998; 40:5356.
  • 85
    Platz K, Mueller C, Willimski C, Mansoorian B, Berg T, Neuhaus R, et al. Indication for mycophenylate mofetil therapy in hepatitis C patients undergoing liver transplantation. Transplant Proc 1998; 30:22322233.
  • 86
    Fasola C, Netto G, Jennings L, Marubashi S, Sanchez E, Molmenti E, et al. Initial clinical evidence that mofetil mycophenolate (MMF) antiviral effects may delay the recurrence of hepatitis C (Hep C) in Hep C liver transplant recipients [abstract]. Hepatology 2000; 32:290A.
  • 87
    Wiesner R, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J, et al. A randomised double blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and steroids in primary liver transplant recipients. Liver Transpl 2001; 7:442450.
  • 88
    Jain A, Kashyap R, Demetris A, Eghstesad B, Pokharna R, Fung J. A prospective randomised trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl 2002; 8:4046.
  • 89
    Neumann U, Univ B, Israel R, Yurie L, Gehlsen K. Early viral kinetics during combination therapy with histamine dihydrochloride and interferon alpha and its prediction of SVR [abstract]. Hepatology 2001; 34:418A.
  • 90
    Lurie Y, Pakula R, Malnick S, Beer-Gabel M, Gehlsen K. Efficacy and safety of combination of histamine dihydrochloride and interferon alpha 2b in a phase II trial in naïve patients with chronic hepatitis C [abstract]. Hepatology 2001; 34:350A.
  • 91
    Brillanti S, Levantesi F, Masi L, Foli M, Bolondi L. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology 2000; 32:630634.
  • 92
    Afdal N, Flamm S, Imperial J, Malet P, Tong M, Herrine S, et al. Analyses of 40 kDA peginterferon alpha 2a in combination with ribavirin, MMF, amantadine or amantadine plus ribavirin in patients that did not respond to rebetron therapy [abstract]. Hepatology 2001; 34:243A.
  • 93
    Andreone P, Gramenzi A, Cursaro C, Biselli M, Di Giammarino L, Grazi G, et al. Interferon plus ribavirin and amantadine in patients with posttransplant hepatitis C: Results of a pilot study. Dig Liver Dis 2001; 33:693697.
  • 94
    Dodson S, Araya V, Balan V, Rakela J, Fung J. Preliminary analysis of treatment of recurrent HCV after liver transplantation with alpha interferon and amantadine [abstract]. Hepatology 1997; 26:157A.